Joint research with academia
SymBio does not have research laboratories like major pharmaceutical companies, but we actively collaborate with excellent academia around the world and promote joint research. This not only reduces the burden of fixed costs for research facilities and researchers, but also allows us to approach cutting-edge research in academia early, develop new therapeutic areas for existing products, explore new indications, and explore and develop new pipelines. We aim to deliver new drugs to "Underserved Therapeutic Areas" as soon as possible by continuously working on in-licensing globally.
Outside of Japan
National Institute of Neurological Disorders and Stroke (NINDS) (USA)
SymBio entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Neurological Disorders and Stroke (NINDS), an affiliate of the National Institutes of Health (NIH), to conduct a preclinical study to evaluate the efficacy of brincidofovir (BCV) in multiple sclerosis (MS) associated with Epstein-Barr virus (EBV) infection.
National Institute of Allergy and Infectious Diseases (NIAID) (USA)
Concluded a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) in the United States, and started preclinical study to evaluate the therapeutic effects against EB virus disease. This has made it possible to evaluate the potential of brincidofovir as a targeted therapy for EB virus disease using animal models that can mimic human disease caused by EB virus infection.
Tufts University (USA)
Regarding brincidofovir (BCV), SymBio entered into a a Sponsored Research Agreement (SRA) with Tufts University in the United States and are proceeding with joint research. This joint research is preclinical study to verify the effect of BCV against herpes simplex virus type 1 (HSV-1) using a 3D brain model established by Tufts University.
National Cancer Centre Singapore (NCCS)
Started joint research with NCCS to explore the therapeutic effect and mechanism of brincidofovir (BCV) against EB virus-positive lymphoma. We are working towards future clinical trials.
University of California, San Francisco (USA)
preclinical study to investigate the therapeutic effects brincidofovir (BCV) on brain tumors was initiated at the University of California San Francisco Neurosurgery and Brain Tumor Center. We are aiming for a new indication for BCV.
Penn State College of Medicine (USA)
Regarding brincidofovir (BCV), SymBio entered into Material Transfer Agreement with Penn State College of Medicine in the United States, and is proceeding with preclinical study to verify the effects of BCV in polyomavirus-infected mouse models.
National Institute of Infectious Diseases
In April 2020, Dr. Nozomu Hanaoka of the National Institute of Infectious Diseases, the Fourth Laboratory of Center for Emergency Preparedness and Response, the National Institute of Infectious Diseases and SymBio started this joint research, and tested 17 types of serotypes, including serotypes whose activity was unknown. Validate the antiviral activity of BCV against different serotypes of adenovirus. As a result, it was newly found that BCV exhibits excellent antiviral activity against types D54 and B11, which cause epidemic keratoconjunctivitis and hemorrhagic cystitis after hematopoietic stem cell transplantation, especially in Japan. A paper based on the findings of this study has been published in Microbiology Spectrum.
University of Tokyo
Collaborate with the University of Tokyo to analyze new usefulness and underlying molecular mechanisms, and to explore new indications for anti-tumor drug therapy, including combination therapy with bendamustine and rigosertib, or various other drugs. In addition to starting joint research, we established a social collaboration course Molecular Oncology Pharmacy.
Joint research is underway with the Department of Hematology and Oncology, Kyoto University Graduate School of Medicine, with the aim of analyzing the mechanism of response to bendamustine in combination with bendamustine and other drugs for the treatment of B-cell lymphoma. We aim to provide a stepping stone for the development of new treatments.